LB01

About Lead Biologics International

Lead Biologics is a preclinical-stage biotech based in Stockholm, pioneering novel antibody-based cancer immunotherapies. The company's core strategy is the discovery of new immune checkpoint and cell surface targets, such as SLAMF6 and C3AR, to develop first-in-class treatments with potentially improved efficacy and safety profiles. It operates through a collaborative model, engaging in academic and industrial partnerships to accelerate development. With three disclosed antibody programs and recent high-profile publication, the company is positioning itself as an emerging player in the next wave of oncology therapeutics.

Therapeutic Areas